Loperamide HCl

N. catalogoS2480 Lotto:S248002

Stampa

Dati tecnici

Formula

C29H33ClN2O2.HCl

Peso molecolare 513.5 Numero CAS 34552-83-5
Solubilità (25°C)* In vitro DMSO 24 mg/mL (46.73 mM)
Ethanol 4 mg/mL (7.78 mM)
Water Insoluble
In vivo (Aggiungere i solventi al prodotto singolarmente e in ordine.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO Corn oil

Convalidato dai laboratori Selleck. Se sono necessarie modifiche a questa formulazione, contattare il nostro team di vendita per test personalizzati.

7.500mg/ml (14.61mM) Taking the 1 mL working solution as an example, add 50 μL of 150 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml significa leggermente solubile o insolubile.
* Si prega di notare che Selleck testa la solubilità di tutti i composti internamente e la solubilità effettiva può differire leggermente dai valori pubblicati. Ciò è normale ed è dovuto a leggere variazioni da lotto a lotto.
* Spedizione a temperatura ambiente (I test di stabilità mostrano che questo prodotto può essere spedito senza alcuna misura di raffreddamento.)

Preparazione delle soluzioni stock

Attività biologica

Descrizione Loperamide HCl (ADL 2-1294, R-18553 cloridrato) è un opioide agonista selettivo del μ-Opioid Receptor con un Ki di 3,3 nM, 15 volte e 350 volte più selettivo rispetto al sottotipo δ e al sottotipo κ del Opioid Receptor, utilizzato contro la diarrea derivante da gastroenterite o malattia infiammatoria intestinale.
Target
μ-opioid receptor δ-opioid receptor
3.3 nM(Ki) 48 nM(Ki)
In vitro

Loperamide exhibits potent affinity and selectivity for the cloned micro (Ki = 3 nM) compared with the delta (Ki = 48 nM) and kappa (Ki = 1156 nM) human opioid receptors. Loperamide potently stimulates [35S]guanosine-5'-O-(3-thio)triphosphate binding with EC50 of 56 nM, and inhibits forskolin-stimulated cAMP accumulation (IC50 = 25 nM) in Chinese hamster ovary cells transfected with the human mu opioid receptor. Loperamide potently inhibits late-phase formalin-induced flinching after intrapaw injection (A50 = 6 mg).Loperamide is a strong inhibitor of CES2, with a K(i) of 1.5 uM, but it only weakly inhibits CES1A1 (IC50 = 0.44 mM).Loperamide reversibly blocks rises in [Ca2+]i evoked by high [K+] in a concentration-dependent manner, with an IC50 of 0.9 mM. Loperamide (0.1-50 mM) produces a concentration-dependent reduction of the peak IBa with an IC50 value of 2.5 mM and, at the highest concentration tested, could fully block IBa in the absence of any other pharmacological agent. Loperamide also attenuates NMDA-evoked currents recorded at a membrane potential of -60 mV, with an IC50 of 73 mM.

In vivo

Loperamide, an opioid agonist unable to cross the blood-brain barrier, inhibits both thermal and mechanical hyperalgesia when s.c. injected, locally over the tibial tumoral mass (7.5-75 mg) or distantly, under the fur of the neck (4 mg/kg) in mice.

Protocollo (da riferimento)

Riferimenti

  • https://pubmed.ncbi.nlm.nih.gov/10087042/
  • https://pubmed.ncbi.nlm.nih.gov/15687373/
  • https://pubmed.ncbi.nlm.nih.gov/8183255/
  • https://pubmed.ncbi.nlm.nih.gov/15894068/

Convalida del prodotto da parte del cliente

<p>Low-micromolar amounts of loperamide inhibit MERS-CoV-induced cytopathology. Huh7 cells in 96-well plates were infected with MERS-CoV isolate EMC/2012 (MOI, 0.005) in the presence of 0 to 8 μM LPM (C). Cells were incubated for 2 days, and cell viability was monitored using an MTS assay. In addition, the potential toxicity of compound treatment only was monitored in parallel mock-infected Huh7 cell cultures. Graphs show the results (averages and standard deviations [SD]) of a representative experiment that was performed in quadruplicate. All experiments were repeated at least twice. For each compound, the calculated EC50, CC50, and SI values are given.</p>

, , Antimicrob Agents Chemother, 2014, 58(8):4875-4884.

Comparison of transit from the stomach over 12 h for animals treated with different concentrations of loperamide, prucalopride, and for DMSO-treated/control animals (dotted line) at 4 h (black), 9 h (light grey), and 12 h (dark grey) (n = 7–13 animals per group). (A) The percentage of rats in which all beads had exited the stomach, and (B) the percentage of beads that had exited the stomach (mean per treatment). Asterisks indicate the significance of each treatment relative to controls (*p < 0.05). Data show mean±SEM

Dati da [ , , Neurogastroenterol Motil, 2016, 28(8):1241-51 ]

Selleck's Loperamide HCl È stato citato da 9 Pubblicazioni

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups [ Cancer Cell, 2025, 43(4):776-796.e14] PubMed: 40185092
Novel insights into mechanisms of inhibition of colonic motility by loperamide [ Front Neurosci, 2024, 18:1424936] PubMed: 39268036
Slowed gastrointestinal transit is associated with an altered caecal microbiota in an aged rat model [ Front Cell Infect Microbiol, 2023, 13:1139152] PubMed: 36998634
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients [ Anticancer Drugs, 2022, 10.1097/CAD.0000000000001344] PubMed: 36066384
Reversal of Infected Host Gene Expression Identifies Repurposed Drug Candidates for COVID-19 [ bioRxiv, 2020, 2020/9/20.4.7.30734] PubMed: 32511305
miR-21 enhances the protective effect of loperamide on rat cardiomyocytes against hypoxia/reoxygenation, reactive oxygen species production and apoptosis via regulating Akap8 and Bard1 expression. [ Exp Ther Med, 2019, 17(2):1312-1320] PubMed: 30680008
Gastric Emptying and Gastrointestinal Transit Compared among Native and Hydrolyzed Whey and Casein Milk Proteins in an Aged Rat Model. [ Nutrients, 2017, 9(12)] PubMed: 29236034
Tracking gastrointestinal transit of solids in aged rats as pharmacological models of chronic dysmotility. [Dalziel JE, et al. Neurogastroenterol Motil, 2016, 28(8):1241-51] PubMed: 27028044
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture [de Wilde AH, et al. Antimicrob Agents Chemother, 2014, 58(8):4875-84] PubMed: 24841269

POLITICA DI RESO
La politica di reso incondizionato di Selleck Chemical garantisce ai nostri clienti un'esperienza di acquisto online senza problemi. Se non sei in alcun modo soddisfatto del tuo acquisto, puoi restituire qualsiasi articolo entro 7 giorni dalla ricezione. In caso di problemi di qualità del prodotto, sia relativi al protocollo che al prodotto, puoi restituire qualsiasi articolo entro 365 giorni dalla data di acquisto originale. Si prega di seguire le istruzioni seguenti per la restituzione dei prodotti.

SPEDIZIONE E CONSERVAZIONE
I prodotti Selleck vengono trasportati a temperatura ambiente. Se ricevi il prodotto a temperatura ambiente, ti assicuriamo che il Dipartimento di Ispezione Qualità di Selleck ha condotto esperimenti per verificare che la conservazione a temperatura normale per un mese non influirà sull'attività biologica dei prodotti in polvere. Dopo la raccolta, conservare il prodotto secondo le indicazioni descritte nella scheda tecnica. La maggior parte dei prodotti Selleck è stabile nelle condizioni raccomandate.

NON PER USO UMANO, DIAGNOSTICO VETERINARIO O TERAPEUTICO.